Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Pool patents to get COVID vaccines and drugs to all

We call on pharmaceutical companies to contribute to a pool of patents set up by the World Health Organization (WHO). That will speed up the manufacture of generic, affordable COVID-19 vaccines and treatments while protecting firms’ incentives to invest in future research. The WHO’s COVID-19 Technology Access Pool has so far received no contributions from industry.

Asking governments in rich nations to donate vaccines to lower-income countries (see G. Yamey Nature 590, 529; 2021) will not hasten manufacture. India and South Africa have proposed suspending patents related to COVID-19 products, but companies contend that this could dent drug development.

The practice of pooling patented technologies for the production of medicines (see Nature 581, 240; 2020) already occurs for HIV, hepatitis C and tuberculosis treatments. Fees are typically lower when licences are negotiated as a bundle with generics producers, implying increased volume (J. Lerner and J. Tirole Innov. Policy Econ. 8, 157–186; 2007). Yet firms can anticipate extra revenue from participation in a voluntary pool, and thus be more willing to maintain innovation and share know-how than with compulsory licensing.

Nature 591, 529 (2021)



Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links